MedPath

Levosimendan

Generic Name
Levosimendan
Drug Type
Small Molecule
Chemical Formula
C14H12N6O
CAS Number
141505-33-1
Unique Ingredient Identifier
C6T4514L4E
Background

Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Indication

For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.

Associated Conditions
Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure
Associated Therapies
Positive cardiac inotropic effect, Intravenous inotropic therapy
Clinical Trials
Related News

Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients

Phase 3
Completed
Conditions
Cardiovascular Risk Factor
Interventions
Drug: Placebo
First Posted Date
2020-04-01
Last Posted Date
2025-05-08
Lead Sponsor
Medical University of Vienna
Target Recruit Count
230
Registration Number
NCT04329624
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Spanish Randomized Clinical Trial to Compare Levosimendan Versus Placebo in Postoperative Cardiac Surgery (SPARTANS)

Phase 2
Conditions
Cardiac Output, Low
Interventions
Drug: Placebos
First Posted Date
2019-11-27
Last Posted Date
2020-07-24
Lead Sponsor
María de los Ángeles Tena Pajuelo
Target Recruit Count
300
Registration Number
NCT04179604
Locations
🇪🇸

Valladolid universitary Hospital, Valladolid, Spain

🇪🇸

GERMANS TRIAS I PUJOL DE BADALONA university Hospital, Badalona, Barcelona, Spain

🇪🇸

12 de Octubre University Hospital, Madrid, Spain

and more 6 locations

Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS

Phase 3
Terminated
Conditions
Acute Decompensated Heart Failure
Interventions
Drug: Cernevit
First Posted Date
2019-11-12
Last Posted Date
2024-10-01
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
82
Registration Number
NCT04158674
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis

Conditions
Sepsis
Septic Shock
Cardiogenic Shock
First Posted Date
2019-10-28
Last Posted Date
2019-10-28
Lead Sponsor
Azienda USL Toscana Centro
Target Recruit Count
35
Registration Number
NCT04141410
Locations
🇮🇹

Ospedale Santo Stefano, Prato, FI, Italy

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

Phase 3
Recruiting
Conditions
Cardiogenic Shock
Interventions
Drug: Placebo
First Posted Date
2019-07-16
Last Posted Date
2024-08-26
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
610
Registration Number
NCT04020263
Locations
🇫🇷

CHRU Strasbourg -Nouvel Hôpital Civil, Strasbourg, Bas-Rhin, France

🇫🇷

CHU Besançon Jean Minjoz Hospital, Besançon, Doubs, France

🇫🇷

CHU Grenoble, Michallon Hospital, La Tronche, Isère, France

and more 28 locations

A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics

Phase 3
Conditions
ARDS, Human
Interventions
First Posted Date
2019-07-15
Last Posted Date
2019-07-15
Lead Sponsor
Shenzhen Second People's Hospital
Target Recruit Count
120
Registration Number
NCT04020003
Locations
🇨🇳

Shenzhen Second People's Hospital, Shenzhen, Guangdong, China

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

Phase 3
Terminated
Conditions
Amyotrophic Lateral Sclerosis
Interventions
First Posted Date
2019-05-13
Last Posted Date
2023-03-09
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
227
Registration Number
NCT03948178
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

🇺🇸

Augusta University, Medical Centre, Augusta, Georgia, United States

🇺🇸

Neurology Associates, Lincoln, Nebraska, United States

and more 76 locations

Levosimendan Versus Milrinone in Off Pump CABG Surgery

Phase 4
Conditions
Hemodynamics
Interventions
First Posted Date
2019-02-27
Last Posted Date
2019-03-07
Lead Sponsor
Assiut University
Target Recruit Count
60
Registration Number
NCT03855579
Locations
🇪🇬

Assiut University, Assiut, Egypt

Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations

Phase 4
Conditions
Systolic Heart Failure
Interventions
First Posted Date
2018-12-05
Last Posted Date
2018-12-05
Lead Sponsor
Collegium Medicum w Bydgoszczy
Target Recruit Count
100
Registration Number
NCT03764722
Locations
🇵🇱

Second Department of Cardiology, Bydgoszcz, Poland

Clinical Trial in Patients Who Have Suffered a Heart Attack and Who Have Undergone Catheterization Treated With Levosimendan

Phase 3
Conditions
ST Elevation Myocardial Infarction
Interventions
Drug: Placebos
First Posted Date
2018-10-09
Last Posted Date
2021-02-11
Lead Sponsor
Hospital Universitario de Canarias
Target Recruit Count
184
Registration Number
NCT03699215
Locations
🇪🇸

UICEC, La Laguna, S/C De Tenerife, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy